Emerging data suggest that p21-activated kinase 1 (Pak1), a downstream signaling molecule of the small GTPases, growth factors, and lipid signaling, is upregulated or hyperactivated in human breast cancer. Until now, however, no direct causative role had been found for Pak1 in mammary tumor formation. We therefore sought to identify the role that Pak1 plays in mammary gland tumorigenesis. Our results showed that in a transgenic mouse model, overexpression of catalytically active Pak1 leads to the development of malignant mammary tumors and to a variety of other breast lesions, including focal solid nodules, ductal hyperplasia, and mini-intraductal neoplasm and adenoma. We also found that Pak1 hyperactivation increases the stimulation of downstream proliferative signaling effectors MEK1/2 and p38-MAPK in mammary tumor epithelial cells. Moreover, in our study, we detected expression of estrogen receptor-alpha expression and progesterone receptor expression during early stages of the lesions, but their expression was lost during the cells' transition to malignant invasive tumors. Finally, we found that consistent with a role in breast tumor progression, Pak1 expression and its nuclear accumulation was increased progressively during the transition from ductal hyperplasia to ductal carcinoma in situ to adenocarcinoma in widely used multistep polyoma-middle T-antigen transgenic mice. Together, these findings provide the first direct evidence that Pak1 deregulation may be sufficient for the formation of mammary gland tumors.
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Pak1 has been linked to a variety of human cancers. For example, Pak1 gene amplification occurs in ovarian (Schraml et al., 2003) and breast cancers (Bekri et al., 1997) ; Pak1 protein is upregulated in ovarian tumors (Schraml et al., 2003) , breast cancers (Vadlamudi et al., 2000; Salh et al., 2002; Balasenthil et al., 2004) , and colorectal carcinomas (Knowles and Phillips, 2001) ; and Pak1 expression correlates well with cyclin D1 expression in breast cancers (Balasenthil et al., 2004) . Adam et al. (1998) reported that Pak1 is activated by a number of extracellular signals, including heregulin and epidermal growth factor, which are potent inducers of Pak1 activity and breast cancer cell motility. These investigations also found that Pak1 activation plays a mechanistic role in increased breast cancer cell invasion. Finally, expression of a kinase-dead Pak1 mutant in the highly invasive breast cancer cell lines MDA-MB-435 and MDA-MB-231 leads to the stabilization of stress fibers, enhanced cell spreading, and a reduction in invasiveness (Adam et al., 1998) . In the noninvasive breast cancer cell line MCF-7, however, Vadlamudi et al. (2000) found that hyperactivation of the Pak1 pathway by conditional expression of catalytically active T423E-Pak1 promotes cell migration and anchorageindependent growth. Further, increased Pak1 activity correlated well with the invasiveness of human breast cancer cells and tumors (Vadlamudi et al., 2000) . In another two studies, Wang et al. (2002 Wang et al. ( , 2003 found that Pak1 was normally expressed in the murine mammary epithelium, and both the expression level and kinase activity regulate changes in the mammary developmental and functional cycles. Targeted expression of a kinase-active T423E Pak1 transgene in the murine mammary gland leads to widespread hyperplasia in the mammary glands. Reversely, ectopic expression of a kinase-dead Pak1 blocked the alveolar development and functional differentiation (Wang et al., 2003) . Despite these observations, the role that Pak1 hyperactivation plays in mammary tumor formation remains unknown. We therefore sought to elucidate the role of Pak1 in mammary gland tumorigenesis in a murine model.
We first investigated the effect that deregulated Pak1 activity has on the process of murine mammary tumorigenesis. We used transgenic mice expressing catalytically active T423E-Pak1 driven by the ovine blactoglobulin promoter . The genetic background of the animals is 25% C57B6 and 75% DBA. As this promoter drives the expression of transgenes only under the influence of lactogenic hormones during pregnancy and lactation, we tried to mimic pregnancy in mice by pituitary isografting (PI) under the left kidney capsule (Medina and Kittrel, 2000) . The donor pituitaries were from the male litermates. Under physiological conditions, the anterior pituitary is tightly controlled by inhibitory and releasing hormones from neurons of the hypothalamus' suprachiasmatic nucleus. Prolactin is released in response to chorionic gonadotropins from the placenta during pregnancy and to suckling stimuli during lactation. However, when the pituitary gland is isografted to a different location, control by the hypothalamus is no longer effective. Free of this control, the pituitary implant constitutively secretes prolactin, which, in addition to its direct mammotropic effects, has strong luteotropic effects. These effects induce the ovarian corpora lutea to synthesize and secrete progesterone, resulting in elevation of serum estrogen and progesterone levels to those generally observed in pregnant mice. Collectively, such a hormonal environment due to PI induces epithelial proliferation and alveolar differentiation in the mammary gland, which in turn results in ductal architecture that resembles the morphological phenotype observed in mice in mid-to-late-pregnancy (Medina and Kittrel, 2000) .
Next, to rule out the possibility of tissue rejection, we evaluated the efficiency of the pituitary isografts. Figure 1a shows the typical pronounced enlargement of the pituitary isograft 12 months after implantation into the Pak1-TG mouse kidney. Histological examination of serial sections of all the pituitary isografts further ruled out any evidence of rejection (Figure 1b) . After 3 weeks of PI, four mice from 8-week-old age-matched control and Pak1-TG mice were euthanized, and a whole-mount analysis of the inguinal mammary glands was performed to determine the responsiveness of the mammary gland to stimulation by the pituitary isograft stimulation. In the absence of a pituitary isograft, no discernible changes were seen in the gross ductal morphologic features (Figure 1c) . However, the inguinal mammary gland from the pituitary-isografted mice displayed extensive ductal arborization and lobuloalveolar development, thus confirming the effectiveness of PI in mimicking the desired reproductive status for transgene expression (Figure 1d) .
To further validate the expression of the transgene, we performed a reverse transcriptase-polymerase chain reaction analysis and found that the transgene was expressed only in the mammary glands of the Pak1-TG mice with pituitary isografts (Figure 1d, insert) , not in the mammary glands from the control mice (Figure 1c , insert). Histological examinations of the mammary glands also revealed lobuloalveolar development in response to the pituitary isograft (Figure 1f) , which did not occur in the control mice (Figure 1e ).
To monitor for tumor development, we maintained 10 Pak1-TG and 10 age-matched wild-type mice that had received pituitary isografts. The mice were examined for palpable tumors every other week for 2 years. Two Pak1-TG mice developed palpable mammary gland tumors, one at 13 months old and the other at 18 months old. Histopathological examinations of the tumors showed comedo-type adenocarcinoma and mixed-type squamous adenocarcinoma (Figures 1g and  h ). In contrast, none of the wild-type mice with pituitary isografts developed palpable tumors during this period. 
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We previously showed that the Pak1-TG mice developed hyperplasia and apocrine metaplasia during lactation when the transgene was highly expressed . To observe the long-term effect of deregulated Pak1 activity on the mammary glands, we studied 30 retired transgenic breeders and 30 agematched, wild-type (control) retired breeders over their remaining lifetime for tumor development. We found that six of the 30 Pak1-TG mice developed palpable mammary tumors, whereas none of the control mice did. Histopathological analyses of the tumors from the Pak1-TG mice revealed heterogeneous tumors ranging from benign adenopathy to adenocarcinoma and adenosquamous carcinoma (Table 1, Figure 2a , b, c and d). The Pak1-TG mice also displayed various types of premalignant lesions, including focal solid nodules which on histological sections exhibited various degrees of ductal hyperplasia up to mini-intraductal neoplasms (MIN) (Figure 2e, f) .
Pak1 reportedly modulates cell growth by activating the MAPK and p38MAPK pathways (Vadlamudi et al., 2000) . To investigate whether these pathways are functional in mammary tumors from Pak1-TG mice, we immunohistochemically examined the status of phosphorylated MEK1/2 and p38MAPK. An interesting finding was that phosphorylated MEK1/2 and (Figures 3a-d) .
Since recent studies have shown the nuclear localization of Pak1 (Vadlamudi et al., 2000; Li et al., 2002; Singh et al., 2005) , we next examined the status of phosphorylated Pak1 in the mammary tumors from Pak1-TG mice. Immunohistochemical staining revealed prevailing nuclear expression of T212-phosphorylated Pak1, which is even more prominent in adenosqumous carcinomas than in the relatively benign adenoma (Figures 3e-i) . This finding further raised the possibility that the activated Pak1 might have a role in breast tumor progression.
Estrogen and progesterone receptors play an important role in the development and progression of mammary tumors. However, most of the mammary gland animal models are estrogen receptor (ER) and progesterone receptor (PR) negative, with the exception of the p53 mouse model (Medina et al., 2003) and the murine mammary tumor virus-Wnt1 model (Bocchinfuso et al., 1999) . Therefore, we next examined the status of ER and PR in Pak1-TG-induced tumors. We found that three out of eight (37.5%) tumors were ER and PR positive (Figures 4a and b) and that such tumors were benign adenomas and/or adenocarcinomas. Loss of ER in mouse models is known to correlate with a tumor's progression to malignancy (Medina et al., 2003) ; we also found that aggressive areas of squamous carcinomas showed no detectable immunostaining of ER or PR, suggesting that Pak1 hyperactivation plays a role in the development of hormone independence in some mammary gland tumors (Figure 4c , d, e and f).
To further link a role of Pak1 in the development of mammary gland tumors, we next examined whether a correlation exists between the Pak1 expression and tumor progression using a well characterized transgenic model of polyoma middle-T antigen transgenic mouse (PyMT-TG) (Guy et al., 1992) . The PyMT transgenic mouse model has proven to be a valuable model for studying breast cancer development and progression, as it reflects the complexity of human breast cancer and the multistep progression from normal to hyperplasia, malignancy, and metastasis (Lin et al., 2003) . The PyMT mouse model recapitulates many features of human breast cancers and has molecular pathways similar to those in human breast cancers (Barkan et al., 2004) . We found that in normal virgin mammary glandular tissue, Pak1 was expressed in the cytoplasm, whereas phosphorylated Pak1 was expressed in the nuclei of luminal epithelial cells. Interestingly, in hyperplastic tissue, Pak1 was localized in both the cytoplasm and the cell nuclei, whereas phosphorylated Pak1 was localized in the cytoplasm only ( Figure 5 ). In benign adenomas and advanced-stage invasive adenocarcinomas, however, Pak1 was strongly expressed in both the cytoplasm and the nuclei, whereas phosphorylated Pak1 was predominantly localized in the nuclei only ( Figure 5 ). In this context, it is worth mentioning that Pak1 has recently been found to be localized in the nuclear compartment of invasive human breast tumors (Singh et al., 2005) . Pak1 has also been shown to contain nuclear localization signals, to localize in the nuclei, to interact with chromatin, and to promote transcription, suggesting that Pak1 could influence the expression of genes with potential roles in tumor progression (Singh et al., 2005) . In brief, the Pak1 nuclear localization in advanced-stage mouse breast cancer that we observed in this study suggests that Pak1 plays an important, yet-tobe-defined role in mammary gland tumorigenesis.
In summary, our findings show for the first time that Pak1 hyperactivation could lead to the formation of mammary gland tumors and that Pak1-induced tumor formation is accompanied by stimulation of the MAPK pathways, which are intimately associated with enhanced cell growth. Since we found a stepwise, cell-typespecific expression pattern of activated Pak1 at different 
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R-A Wang et al stages of tumor formation, we hypothesize that overexpression or overactivation of Pak1 plays a role in both mammary oncogenesis and tumor progression. The relatively long latency period and low penetrance of tumor development suggest that Pak1-induced tumorigenesis requires an accumulation of other genetic events.
The mouse model of progression breast cancer we used offers new opportunities to determine the effects of Pak1 on ER-dependent and -independent events during mammary tumorigenesis. As the Pak1 pathway is widely upregulated in human breast tumors and now has been causally linked to the formation of breast tumors, our new evidence strengthens the notion that therapies targeting the Pak1 pathway can be developed to retard the growth of mammary gland tumors.
